Basic Information
| LncRNA/CircRNA Name | PAGBC |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gallbladder cancer |
| ICD-0-3 | C23.9 |
| Methods | qPCR, Microarray, Western blot, Luciferase reporter assay, RIP etc. |
| Sample | cell lines (GBC-SD, SGC-996, NOZ, EH-GB) |
| Expression Pattern | down-regulated |
| Function Description | In this study, we identify a group of differentially expressed lncRNAs in human GBC tissues, including prognosisassociated gallbladder cancer lncRNA (lncRNA-PAGBC), which we find to be an independent prognostic marker in GBC. Functional analysis indicates that lncRNA-PAGBC promotes tumour growth and metastasis of GBC cells. More importantly, as a competitive endogenous RNA (ceRNA), lncRNA-PAGBC competitively binds to the tumour suppressive microRNAs miR-133b and miR-511. This competitive role of lncRNA-PAGBC is required for its ability to promote tumour growth and metastasis and to activate the AKT/mTOR pathway. |
| Pubmed ID | 28887321 |
| Year | 2017 |
| Title | LncRNA-PAGBC acts as a microRNA sponge and promotes gallbladder tumorigenesis |
External Links
| Links for PAGBC | GenBank HGNC NONCODE |
| Links for gallbladder cancer | OMIM COSMIC |